Noble Wealth Management PBC’s PTC Therapeutics PTCT Stock Holding History

Noble Wealth Management PBC’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-10	Closed	-$816	–	857
2026 Q2	$816	Buy	+10	New	+$722	﹤0.01%	740

Other funds holding PTCT

Juncture Wealth Strategies Scottsdale, Arizona $390M AUM 19.15% 1-Year Est. Return

Private Capital Advisors Darien, Connecticut $1.15B AUM 43.46% 1-Year Est. Return

Sacks & Associates Warren, New Jersey $143M AUM 17.48% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return

Davis Capital Management Jacksonville, Florida $167M AUM 17.17% 1-Year Est. Return

Noble Wealth Management PBC's PTCT Position: Q3 2026 in Review

Noble Wealth Management PBC sold out of PTC Therapeutics (PTCT) in Q3 2026, closing a stake of 10 shares — an estimated $816 sold.

Noble Wealth Management PBC first reported a position in PTCT in Q2 2026 and held it in 1 quarter. The position peaked at $816 in Q2 2026. 8 funds tracked by Wall St. Rank hold PTCT as of Q3 2026.

Noble Wealth Management PBC reported no remaining PTC Therapeutics position as of Q3 2026 after selling out during the quarter.
Noble Wealth Management PBC sold 10 PTC Therapeutics shares in Q3 2026, an estimated $816.
Noble Wealth Management PBC first reported a position in PTC Therapeutics in Q2 2026 and held it in 1 quarter.
Noble Wealth Management PBC's PTC Therapeutics position peaked at $816 in Q2 2026.
8 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2026.

Based on Noble Wealth Management PBC's 13F filing for Q3 2026, filed 1 Oct 2026.